Immune Priming with Spatially Fractionated Radiation Therapy-Reference-Cited by-同舟云学术

Immune Priming with Spatially Fractionated Radiation Therapy

Published:2023-11-18 Issue:12 Volume:25 Page:1483-1496
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Lukas Lauren,Zhang Hualin,Cheng Karen,Epstein Alan

Abstract

Abstract Purpose of Review This review aims to summarize the current preclinical and clinical evidence of nontargeted immune effects of spatially fractionated radiation therapy (SFRT). We then highlight strategies to augment the immunomodulatory potential of SFRT in combination with immunotherapy (IT). Recent Findings The response of cancer to IT is limited by primary and acquired immune resistance, and strategies are needed to prime the immune system to increase the efficacy of IT. Radiation therapy can induce immunologic effects and can potentially be used to synergize the effects of IT, although the optimal combination of radiation and IT is largely unknown. SFRT is a novel radiation technique that limits ablative doses to tumor subvolumes, and this highly heterogeneous dose deposition may increase the immune-rich infiltrate within the targeted tumor with enhanced antigen presentation and activated T cells in nonirradiated tumors. Summary The understanding of nontargeted effects of SFRT can contribute to future translational strategies to combine SFRT and IT. Integration of SFRT and IT is an innovative approach to address immune resistance to IT with the overall goal of improving the therapeutic ratio of radiation therapy and increasing the efficacy of IT.

Funder

University of Southern California

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11912-023-01473-7.pdf

Reference69 articles.

1. Valenza C, Rizzo G, Passalacqua MI, Boldrini L, Corti C, Trapani D, Curigliano G. Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives. Ther Adv Med Oncol. 2023;15:17588359221146129. https://doi.org/10.1177/17588359221146129.

2. Sun K, Xu Y, Zhang L, Niravath P, Darcourt J, Patel T, Teh BS, Farach AM, Guerrero C, Mathur S, Sultenfuss MA, Gupta N, Schwartz MR, Haley SL, Nair S, Li X, Nguyen TTA, Butner JD, Ensor J, et al. A phase 2 trial of enhancing immune checkpoint blockade by stereotactic radiation and in situ virus gene therapy in metastatic triple-negative breast cancer. Clin Cancer Res. 2022;28(20):4392–401. https://doi.org/10.1158/1078-0432.Ccr-22-0622.

3. Dutt S, Ahmed MM, Loo BW Jr, Strober S. Novel radiation therapy paradigms and immunomodulation: heresies and hope. Semin Radiat Oncol. 2020;30(2):194–200. https://doi.org/10.1016/j.semradonc.2019.12.006.

4. Borzov E, Bar-Deroma R, Lutsyk M. Physical aspects of a spatially fractionated radiotherapy technique for large soft tissue sarcomas. Phys Imaging Radiat Oncol. 2022;22:63–6. https://doi.org/10.1016/j.phro.2022.04.010.

5. •• Johnsrud AJ, Jenkins SV, Jamshidi-Parsian A, Quick CM, Galhardo EP, RPM D, Vang KB, Narayanasamy G, Makhoul I, Griffin RJ. Evidence for early stage anti-tumor immunity elicited by spatially fractionated radiotherapy-immunotherapy combinations. Radiat Res. 2020;194(6):688–97. https://doi.org/10.1667/rade-20-00065.1. This study represents an important preclinical assesssment of immune effects from combination SFRT and IT. The study suggests that systemic immune activation may be triggered by SFRT to a primary lesion and promote anti-tumor immune responses outside the treatment field.